Search
for

    Sort by

    Community Join

    990-1000 / 1000+ results

      community Opinions on this study for Triphasic Progressive by Rene Furterer

      in Research/Science  14 upvotes 2 years ago
      The user shared their 5-year hair loss journey, initially using a product called Triphasic Progressive by Rene Furterer, which gave good results. Later, they switched to FDA-approved medications finasteride and minoxidil, which also helped, but they noticed the most significant progress with Triphasic. They're considering trying it again if minoxidil doesn't show improvements.

      community 1 year on fin. Take the pill. NOW.

      in Progress Pictures  353 upvotes 2 years ago
      After one year on finasteride, a user reports positive hair regrowth and minimal side effects, encouraging others to try the treatment despite potential risks. Other users share varied experiences with finasteride, some seeing improvements and others still waiting for results.

      community 4 mont fin min and dermarolling

      in Progress Pictures  20 upvotes 1 year ago
      The user experienced improved self-confidence and hair regrowth using finasteride, minoxidil, and dermarolling. Visible results were noted after about three months, with microneedling done once a week.

      community Is the Ru58841 hype justified?

      in Treatment  18 upvotes 1 year ago
      RU58841 is debated for hair regrowth, with some users reporting no benefits and potential side effects, while others claim success when combined with dutasteride. Many suggest safer, well-researched treatments like finasteride and minoxidil for hair loss management.

      community If PP405 works it will be fkn impossible to buy it.

      in Technology  102 upvotes 7 months ago
      PP405 is a potential hair loss treatment that may activate dormant hair follicles, but there are concerns about its effectiveness, cost, and side effects. Users discuss treatments like minoxidil, finasteride, and RU58841, expressing skepticism about PP405's long-term success and accessibility.